Beijing’s Pharma Kickback Crackdown: 5 Compliance Moves for Foreign Drugmakers
Beijing is widening its pharmaceutical anti-kickback crackdown beyond hospital procurement to sales teams, conferences, and distributors. Five compliance moves for foreign drugmakers in China's second-largest pharma market.
How Innovent Biologics Achieved Global Clinical Trial Leadership: Case Study
How Innovent Biologics Achieved Global Clinical Trial Leadership: Case Study body{font-family:'Segoe UI',Tahoma,Geneva,Verdana,sans-serif;line-height:
How to Manage Batch Release Testing for Importers in China: 2026 Guide
How to Manage Batch Release Testing for Importers in China: 2026 Guide body { font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Helv
China NRDL Pricing Calculator for Foreign Pharma Companies
China NRDL Pricing Calculator for Foreign Pharma Companies body { font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif; line
Essential Clinical Trial Resources for Foreign Pharma Sponsors in China
Essential Clinical Trial Resources for Foreign Pharma Sponsors in China body { font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, san
Essential Drug Registration Resources for Foreign Pharma Companies in China
Essential Drug Registration Resources for Foreign Pharma Companies in China In 2023, the National Medical Products Administration (NMPA) processed ove